Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT06322433
Recruiting Observational

Follow up of High Myopic Eyes

NCT06322433 · tracked via the Priya Life Science Italy tracker
Sponsor
Istituto Auxologico Italiano
Phase
Observational
Started
2023-11-01
Last updated
2025-05-01

Condition(s) studied

Pathologic Myopia

Investigational drug(s) / intervention(s)

no drugs used for this study

no drugs used for this study: tomographic, angiographic and clinical follow up

Study summary

In this non-interventional retrospective and prospective observational study, the long-term evolution of clinical and iconographic characteristics of patients with pathological myopia will be considered Changes of some specific clinical, tomographic and angiographic variables evaluated on the baseline and after a minimum of 5 years follow-up will be studied.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: \- high myopia Exclusion Criteria: * acute ischemic optic neuropathy * macular and peripapillary atrophy * other forms of maculopathy

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Istituto Auxologico Italiano IRCCS Milan Italy Recruiting

More Istituto Auxologico Italiano trials in Italy

MASked-unconTrolled hypERtension Management Based on Office BP or on Out-of-office (Ambulatory) BP Measurement Recruiting
Sleep and Activity For Eating Disorders Starting soon
Study of the Steroid Hormone Milieu in Obese Patients Recruiting
Definition of Mutational Profile of Papillary Thyroid Tumors by Mass-ARRAY Recruiting
Impact of Conventional Treatments and Clinical Variables on Thyroid Cancer Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06322433 on ClinicalTrials.gov ↗ ← All trials in Italy